Orchid Pharma Q2 FY27: Revenue Up 14% to ₹341 Cr, EBITDA Surges 148% to ₹52 Cr
Orchid Pharma reported Q2 FY27 revenue of ₹341 Cr, a 14% YoY increase. EBITDA surged 148% to ₹52 Cr, with margins improving to 15%. Profit after tax was ₹28.6 Cr. H1 FY27 revenue reached ₹645 Cr. The company is integrating the Dhanuka merger, expecting benefits by end of FY27. EXBLIFEP platform shows promise with significant international sales potential.
The substantial increase in revenue and profitability, coupled with significant improvements in EBITDA margins and progress on key strategic projects like 7-ACA and cefiderocol, are material financial and operational developments that are likely to have a high impact on the company's valuation and investor sentiment.
The company reported strong year-on-year growth in revenue and a significant surge in EBITDA and profitability, indicating a positive operational performance. Improvements in gross margins and strategic project updates also contribute to a positive outlook.
Orchid Pharma Limited announced its financial results for the second quarter and first half of Financial Year 2026-27, ending September 30, 2026. The company reported a 14% year-on-year increase in revenue from operations to ₹341 crores for Q2 FY27, up from ₹299 crores in Q2 FY26. Sequentially, revenue grew by approximately 12%. Gross margins improved significantly by around 8 percentage points to 39%, driven by normalization of inventory and a favorable product mix. EBITDA, including other income, surged by 148% to ₹52 crores from ₹21 crores in the prior year's quarter, with EBITDA margins improving to 15% from 7%. This performance was achieved despite headwinds such as a nearly 30% increase in fuel and energy costs and one-time accounting adjustments including an expected credit loss provision of ₹5 crores and an impairment loss of ₹5 crores related to the Dhanuka Laboratories merger. Profit after tax for the quarter stood at ₹28.6 crores, compared to a loss of ₹0.9 crores in Q2 FY26.
For the first half of FY27, revenue grew by 15% to ₹645 crores from ₹562 crores in H1 FY26. Gross margins improved by approximately 6 percentage points to 36%, and EBITDA rose by 148% to ₹77 crores from ₹31 crores, with EBITDA margins at 12% from 6%. Profit after tax for H1 FY27 was approximately ₹32 crores.
The company is focusing on integrating the Dhanuka Laboratories merger, expecting benefits to become visible by the end of FY27. Business updates include the AMS business EBITDA drag reducing to ₹1.5 crores. The EXBLIFEP platform is generating recurring income, with estimated 10-year sales of $178 million in Russia and $80 million in Latin America. Discussions for potential partnerships are ongoing in Australia, Southeast Asia, Japan, and North Africa, with expectations to sign three to four additional license agreements in the next two quarters.
The cefiderocol project is at an advanced stage with ₹173 crores invested, targeting commissioning by December 2026 and India launch by Q3 FY27. The 7-ACA project in Jammu is nearing completion, with commercial operations scheduled for March 2027. Management highlighted that while Q2 and H1 show encouraging improvement, a straight-line recovery is not expected due to competitive pricing and demand in core markets. Priorities include protecting the core business, cost control, executing the 7-ACA and cefiderocol projects, and long-term resilience through backward integration and strategic projects.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.